{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T07:58:48Z","timestamp":1785225528879,"version":"3.55.0"},"reference-count":78,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T00:00:00Z","timestamp":1643846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["TO10-13, SFB1192"],"award-info":[{"award-number":["TO10-13, SFB1192"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Membranous nephropathy (MN) is a rare but potentially severe autoimmune disease and a major cause of nephrotic syndrome in adults. Traditional treatments for patients with MN include steroids with alkylating agents such as cyclophosphamide or calcineurin inhibitors such as cyclosporine, which have an undesirable side effect profile. Newer therapies like rituximab, although superior to cyclosporine in maintaining disease remission, do not only affect pathogenic B or plasma cells, but also inhibit the production of protective antibodies and therefore the ability to fend off foreign organisms and to respond to vaccination. These are undesired effects of general B or plasma cell-targeted treatments. The discovery of several autoantigens in patients with MN offers the great opportunity for more specific treatment approaches. Indeed, such treatments were recently developed for other autoimmune diseases and tested in different preclinical models, and some are about to jump to clinical practice. As such treatments have enormous potential to enhance specificity, efficacy and compatibility also for MN, we will discuss two promising strategies in this perspective: The elimination of pathogenic antibodies through endogenous degradation systems and the depletion of pathogenic B cells through chimeric autoantibody receptor T cells.<\/jats:p>","DOI":"10.3389\/fimmu.2022.822508","type":"journal-article","created":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T05:33:07Z","timestamp":1643866387000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":26,"title":["Strategies Towards Antigen-Specific Treatments for Membranous Nephropathy"],"prefix":"10.3389","volume":"13","author":[{"given":"Sarah M. S.","family":"K\u00f6llner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa","family":"Seifert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunther","family":"Zahner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola M.","family":"Tomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,2,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","article-title":"KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases","volume":"100","year":"2021","journal-title":"Kidney Int"},{"key":"B2","article-title":"Nephrotic Glomerulonephritis","volume":"33","author":"Jones","year":"1957","journal-title":"Am J Pathol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012895","article-title":"Antenatal Membranous Glomerulonephritis Due to Anti-Neutral Endopeptidase Antibodies","volume":"346","author":"Debiec","year":"2002","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa0810457","article-title":"M-Type Phospholipase A2 Receptor as Target Antigen in Idiopathic Membranous Nephropathy","volume":"361","author":"Beck","year":"2009","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409354","article-title":"Thrombospondin Type-1 Domain-Containing 7A in Idiopathic Membranous Nephropathy","volume":"371","author":"Tomas","year":"2014","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2019.09.014","article-title":"Neural Epidermal Growth Factor-Like 1protein (NELL-1) Associated Membranous Nephropathy","volume":"97","author":"Sethi","year":"2020","journal-title":"Kidney Int"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2020.05.030","article-title":"Semaphorin 3B-Associated Membranous Nephropathy is a Distinct Type of Disease Predominantly Present in Pediatric Patients","volume":"98","author":"Sethi","year":"2020","journal-title":"Kidney Int"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2020081165","article-title":"Protocadherin 7-Associated Membranous Nephropathy","volume":"32","author":"Sethi","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2020.09.016","article-title":"Neural Cell Adhesion Molecule 1 is a Novel Autoantigen in Membranous Lupus Nephritis","volume":"100","author":"Caza","year":"2021","journal-title":"Kidney Int"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2020101395","article-title":"Serine Protease HTRA1 as a Novel Target Antigen in Primary Membranous Nephropathy","volume":"32","author":"Al-Rabadi","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009742","article-title":"Risk HLA-DQA1 and PLA(2)R1 Alleles in Idiopathic Membranous Nephropathy","volume":"364","author":"Stanescu","year":"2011","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2016010093","article-title":"Long-Term Exposure to Air Pollution and Increased Risk of Membranous Nephropathy in China","volume":"27","author":"Xu","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1511702","article-title":"A Mechanism for Cancer-Associated Membranous Nephropathy","volume":"374","author":"Hoxha","year":"2016","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2016010050","article-title":"An Indirect Immunofluorescence Method Facilitates Detection of Thrombospondin Type 1 Domain-Containing 7a-Specific Antibodies in Membranous Nephropathy","volume":"28","author":"Hoxha","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.22440","article-title":"THSD7A Expression in Human Cancer","volume":"56","author":"Stahl","year":"2017","journal-title":"Genes Chromosomes Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.574997","article-title":"Th17-Immune Response in Patients With Membranous Nephropathy Is Associated With Thrombosis and Relapses","volume":"11","author":"Cremoni","year":"2020","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2021.155452","article-title":"Altered Th17\/Treg Ratio as a Possible Mechanism in Pathogenesis of Idiopathic Membranous Nephropathy","volume":"141","author":"Motavalli","year":"2021","journal-title":"Cytokine"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2017.01.012","article-title":"B- and T-Cell Subpopulations in Patients With Severe Idiopathic Membranous Nephropathy may Predict an Early Response to Rituximab","volume":"92","author":"Rosenzwajg","year":"2017","journal-title":"Kidney Int"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s00441-021-03429-4","article-title":"Perspectives in Membranous Nephropathy","volume":"385","author":"Tomas","year":"2021","journal-title":"Cell Tissue Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1172\/JCI85265","article-title":"Autoantibodies Against Thrombospondin Type 1 Domain-Containing 7A Induce Membranous Nephropathy","volume":"126","author":"Tomas","year":"2016","journal-title":"J Clin Invest"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2013040430","article-title":"Phospholipase A2 Receptor Autoantibodies and Clinical Outcome in Patients With Primary Membranous Nephropathy","volume":"25","author":"Hoxha","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2019.10.022","article-title":"A Novel Mouse Model of Phospholipase A2 Receptor 1-Associated Membranous Nephropathy Mimics Podocyte Injury in Patients","volume":"97","author":"Meyer-Schwesinger","year":"2020","journal-title":"Kidney Int"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1013792","article-title":"Early-Childhood Membranous Nephropathy Due to Cationic Bovine Serum Albumin","volume":"364","author":"Debiec","year":"2011","journal-title":"N Engl J Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S0140-6736(15)60731-0","article-title":"Pathophysiological Advances in Membranous Nephropathy: Time for a Shift in Patient's Care","volume":"2015","author":"Ronco","year":"9981","journal-title":"Lancet"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2005010028","article-title":"Management of Membranous Nephropathy: When and What for Treatment","volume":"16","author":"Cattran","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198404123101503","article-title":"Controlled Trial of Methylprednisolone and Chlorambucil in Idiopathic Membranous Nephropathy","volume":"310","author":"Ponticelli","year":"1984","journal-title":"N Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1995.453","article-title":"A 10-Year Follow-Up of a Randomized Study With Methylprednisolone and Chlorambucil in Membranous Nephropathy","volume":"48","author":"Ponticelli","year":"1995","journal-title":"Kidney Int"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1995.161","article-title":"A Controlled Trial of Cyclosporine in Patients With Progressive Membranous Nephropathy. Canadian Glomerulonephritis Study Group","volume":"47","author":"Cattran","year":"1995","journal-title":"Kidney Int"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2001.0590041484.x","article-title":"Cyclosporine in Patients With Steroid-Resistant Membranous Nephropathy: A Randomized Trial","volume":"59","author":"Cattran","year":"2001","journal-title":"Kidney Int"},{"key":"B30","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1056\/NEJMoa1814427","article-title":"Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy","volume":"381","author":"Fervenza","year":"2019","journal-title":"N Engl J Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2020071091","article-title":"Rituximab or Cyclophosphamide in the Treatment of Membranous Nephropathy: The RI-CYCLO Randomized Trial","volume":"32","author":"Scolari","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.3.1109","article-title":"Fc gammaRIIIa-158v\/F Polymorphism Influences the Binding of IgG by Natural Killer Cell Fc gammaRIIIa, Independently of the Fc gammaRIIIa-48l\/R\/H Phenotype","volume":"90","author":"Koene","year":"1997","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1172\/JCI119616","article-title":"A Novel Polymorphism of FcgammaRIIIa (CD16) Alters Receptor Function and Predisposes to Autoimmune Disease","volume":"100","author":"Wu","year":"1997","journal-title":"J Clin Invest"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/74704","article-title":"Inhibitory Fc Receptors Modulate In Vivo Cytotoxicity Against Tumor Targets","volume":"6","author":"Clynes","year":"2000","journal-title":"Nat Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.3.1038","article-title":"The Mechanism of Tumor Cell Clearance by Rituximab In Vivo in Patients With B-Cell Chronic Lymphocytic Leukemia: Evidence of Caspase Activation and Apoptosis Induction","volume":"99","author":"Byrd","year":"2002","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb8008","article-title":"Binding Mechanisms of Therapeutic Antibodies to Human CD20","volume":"369","author":"Kumar","year":"2020","journal-title":"Science"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaz9356","article-title":"Structure of CD20 in Complex With the Therapeutic Monoclonal Antibody Rituximab","volume":"367","author":"Rouge","year":"2020","journal-title":"Science"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2011.02.009","article-title":"Rituximab Resistance","volume":"24","author":"Rezvani","year":"2011","journal-title":"Best Pract Res Clin Haematol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(20)30270-8","article-title":"B-Cell Depletion With Rituximab in the COVID-19 Pandemic: Where do We Stand","volume":"2","author":"Mehta","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00682","article-title":"Unraveling the Interaction Between FcRn and Albumin: Opportunities for Design of Albumin-Based Therapeutics","volume":"5","author":"Sand","year":"2014","journal-title":"Front Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0063236","article-title":"Engineered Monoclonal Antibody With Novel Antigen-Sweeping Activity In Vivo","volume":"8","author":"Igawa","year":"2013","journal-title":"PloS One"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1143","article-title":"Engineering the Fc Region of Immunoglobulin G to Modulate In Vivo Antibody Levels","volume":"23","author":"Vaccaro","year":"2005","journal-title":"Nat Biotechnol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0854.2009.00887.x","article-title":"Analyses of the Recycling Receptor, FcRn, in Live Cells Reveal Novel Pathways for Lysosomal Delivery","volume":"10","author":"Gan","year":"2009","journal-title":"Traffic"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12392","article-title":"Sweeping Antibody as a Novel Therapeutic Antibody Modality Capable of Eliminating Soluble Antigens From Circulation","volume":"270","author":"Igawa","year":"2016","journal-title":"Immunol Rev"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2011.11.029","article-title":"Reduction of Total IgE by Targeted Coengagement of IgE B-Cell Receptor and FcgammaRIIb With Fc-Engineered Antibody","volume":"129","author":"Chu","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00520","article-title":"IgG Subclasses and Allotypes: From Structure to Effector Functions","volume":"5","author":"Vidarsson","year":"2014","journal-title":"Front Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2005.06.037","article-title":"Molecular Analysis of Expression and Function of Hfcgammariibl and B2 Isoforms in Myeloid Cells","volume":"43","author":"Joshi","year":"2006","journal-title":"Mol Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(89)90846-5","article-title":"Fc Receptor Isoforms Exhibit Distinct Abilities for Coated Pit Localization as a Result of Cytoplasmic Domain Heterogeneity","volume":"58","author":"Miettinen","year":"1989","journal-title":"Cell"},{"key":"B49","article-title":"Hepatic Uptake of Circulating IgG Immune Complexes","volume":"55","author":"Skogh","year":"1985","journal-title":"Immunology"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1202017","article-title":"FcgammaRIIb on Liver Sinusoidal Endothelium Clears Small Immune Complexes","volume":"189","author":"Ganesan","year":"2012","journal-title":"J Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1401470","article-title":"Inhibitory FcgammaRIIb-Mediated Soluble Antigen Clearance From Plasma by a pH-Dependent Antigen-Binding Antibody and Its Enhancement by Fc Engineering","volume":"195","author":"Iwayanagi","year":"2015","journal-title":"J Immunol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15314","article-title":"Engineered Clearing Agents for the Selective Depletion of Antigen-Specific Antibodies","volume":"8","author":"Devanaboyina","year":"2017","journal-title":"Nat Commun"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2020.11.017","article-title":"Selective Depletion of Antigen-Specific Antibodies for the Treatment of Demyelinating Disease","volume":"29","author":"Sun","year":"2021","journal-title":"Mol Ther"},{"key":"B54","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1681\/ASN.2013121315","article-title":"Identification of the Immunodominant Epitope Region in Phospholipase A2 Receptor-Mediating Autoantibody Binding in Idiopathic Membranous Nephropathy","volume":"26","author":"Kao","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2014050502","article-title":"Identification of a Major Epitope Recognized by PLA2R Autoantibodies in Primary Membranous Nephropathy","volume":"26","author":"Fresquet","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2014111061","article-title":"Epitope Spreading of Autoantibody Response to PLA2R Associates With Poor Prognosis in Membranous Nephropathy","volume":"27","author":"Seitz-Polski","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-Term Follow-Up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults With B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"B59","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"B60","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric Antigen Receptor Therapy","volume":"379","author":"June","year":"2018","journal-title":"N Engl J Med"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf6756","article-title":"Reengineering Chimeric Antigen Receptor T Cells for Targeted Therapy of Autoimmune Disease","volume":"353","author":"Ellebrecht","year":"2016","journal-title":"Science"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1172\/JCI138416","article-title":"Antigen-Specific B Cell Depletion for Precision Therapy of Mucosal Pemphigus Vulgaris","volume":"130","author":"Lee","year":"2020","journal-title":"J Clin Invest"},{"key":"B63","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1681\/ASN.2019030273","article-title":"Clinical Relevance of Domain-Specific Phospholipase A2 Receptor 1 Antibody Levels in Patients With Membranous Nephropathy","volume":"31","author":"Reinhard","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2017070805","article-title":"The Most N-Terminal Region of THSD7A Is the Predominant Target for Autoimmunity in THSD7A-Associated Membranous Nephropathy","volume":"29","author":"Seifert","year":"2018","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1002\/prot.25640","article-title":"Structure and Function Insights Garnered From in Silico Modeling of the Thrombospondin Type-1 Domain-Containing 7A Antigen","volume":"87","author":"Stoddard","year":"2019","journal-title":"Proteins"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-16-0040","article-title":"Identification of Predictive Biomarkers for Cytokine Release Syndrome After Chimeric Antigen Receptor T-Cell Therapy for Acute Lymphoblastic Leukemia","volume":"6","author":"Teachey","year":"2016","journal-title":"Cancer Discov"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.756","article-title":"Cytokine Release Syndrome With Chimeric Antigen Receptor T Cell Therapy","volume":"25","author":"Frey","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity After Adoptive Immunotherapy With CD19 CAR-T Cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov"},{"key":"B69","article-title":"First-In-Man Clinical Trial of CAR NK-92 Cells: Safety Test of CD33-CAR NK-92 Cells in Patients With Relapsed and Refractory Acute Myeloid Leukemia","volume":"8","author":"Tang","year":"2018","journal-title":"Am J Cancer Res"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0052-1","article-title":"NK Cells for Cancer Immunotherapy","volume":"19","author":"Shimasaki","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-19-0893","article-title":"Characterization of 7A5: A Human CD137 (4-1bb) Receptor Binding Monoclonal Antibody With Differential Agonist Properties That Promotes Antitumor Immunity","volume":"19","author":"Kotanides","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-016-1792-y","article-title":"Selection and Expansion of Natural Killer Cells for NK Cell-Based Immunotherapy","volume":"65","author":"Becker","year":"2016","journal-title":"Cancer Immunol Immunother"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.673276","article-title":"CAR-NK Cell: A New Paradigm in Tumor Immunotherapy","volume":"11","author":"Marofi","year":"2021","journal-title":"Front Oncol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3083.2009.02308.x","article-title":"How do Regulatory T Cells Work","volume":"70","author":"Corthay","year":"2009","journal-title":"Scand J Immunol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1701800","article-title":"Targeting Antigen-Specific B Cells Using Antigen-Expressing Transduced Regulatory T Cells","volume":"201","author":"Zhang","year":"2018","journal-title":"J Immunol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2016040449","article-title":"Rituximab for Severe Membranous Nephropathy: A 6-Month Trial With Extended Follow-Up","volume":"28","author":"Dahan","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2017010030","article-title":"A Heterologous Model of Thrombospondin Type 1 Domain-Containing 7a-Associated Membranous Nephropathy","volume":"28","author":"Tomas","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00326","article-title":"Emerging Approaches for Regulation and Control of CAR T Cells: A Mini Review","volume":"11","author":"Brandt","year":"2020","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.822508\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T05:33:11Z","timestamp":1643866391000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.822508\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,3]]},"references-count":78,"alternative-id":["10.3389\/fimmu.2022.822508"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.822508","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,3]]},"article-number":"822508"}}